Sufferers of carcinoid syndrome diarrhea, a condition in which serotonin is overproduced by tumors, experience uncontrolled diarrhea that in turn can affect a person’s weight, nutrition, hydration and heart valve function, among other effects. The U.S. Food and Drug Administration has recently approved Xermelo, an oral medication, as a treatment option for use along with somatostatin analog (SSA) therapy when the latter insufficiently addresses the patient’s condition.